A Randomised, Double-blind, Double-dummy, Placebo-controlled, Parallel-group Multi-centre Clinical Proof-of-principle Trial in Adult Subjects With Newly Diagnosed Type 1 Diabetes Mellitus Investigating the Effect of NNC0114-0006 and Liraglutide on Preservation of Beta-cell Function
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 21 Mar 2018
At a glance
- Drugs Anti-interleukin-21 monoclonal antibody (Primary) ; Liraglutide (Primary)
- Indications Type 1 diabetes mellitus
- Focus Pharmacokinetics; Proof of concept
- Sponsors Novo Nordisk
- 22 Sep 2017 Planned End Date changed from 14 Apr 2019 to 1 Mar 2019.
- 22 Sep 2017 Status changed from recruiting to active, no longer recruiting.
- 10 Jun 2017 Biomarkers information updated